For-Robin, Inc. Information

For-Robin Therapeutics, (F-R), is an antibody immunotherapy company, founded in 2012 by Dr. Kate Rittenhouse-Olson. The company name is in honor of Robin Quataert, the Founder’s sister, who died at age 31 of estrogen and progesterone receptor negative breast cancer. For-Robin’s primary mission is treating breast cancer patients. Our proprietary technology (the monoclonal antibody JAA-F11 and humanized variants of it) targets all breast cancer cell subtypes including triple negative breast cancer which currently has no targeted therapy. In addition, this technology should be applicable to colon, prostate, and bladder carcinoma patient populations. For-Robin plans to bring its core humanized JAA-F11 technology as an adjunct therapy to patient populations as quickly, safely and efficaciously as possible.